Farzaneh Foroughinia - Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Afshin Borhani-Haghighi - Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Department of Neurology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Elaheh Jamshidi - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
Haniyeh Javanmardi - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

Patients undergoing Carotid Artery Stenting (CAS) may encounter serious complications including Intracranial hemorrhage (ICH). ICH after carotid re-vascularization has been usually attributed to cerebral hyperperfusion syndrome (CHS) and it is reported as a significant cause of mortality and morbidity. Factors mentioned as risk factors for ICH after carotid intervention are preoperative hypertension, renal failure, bilateral carotid disease or contralateral carotid occlusion, impaired cerebrovascular reserve, female gender, age, nonselective admission, increased Charlson comorbidities score. In this study, we report two cases of ICH after CAS in patients receiving dual antiplatelet regimen plus omega-3 fatty acids before and after carotid intervention. It seems that administration of omega 3 with other antiplatelets could augment inhibition of platelet aggregation and may increase the risk of ICH in patients undergoing CAS especially in those with several risk factors for ICH. These findings are important because of the wide availability of omega-3 supplements as an over-the-counter (OTC) drug and the propensity for usage of it in alternative medicine.

Intracranial Hemorrhage, Carotid artery stenting, Fatty acids, Omega-3, Dual antiplatelets